Angle plc

finnCap Capital Markets is delighted to have advised ANGLE plc on its £20m Placing, accelerating further clinical applications for Parsortix® and exploit the first-mover advantage that the FDA clearance for Parsortix® will create.

The funds will be used to develop a pre-biopsy test for prostate cancer, expanding its assay development capabilities for its pharma services business and strengthening management in the US to capitalise on the enormous opportunity that the adoption of liquid biopsies in this market offers. It also funds the ongoing operations for breast cancer and ovarian cancer, and strengthens the balance sheet for pharma services, which received its first substantial contract announced in April.

Carl Holmes, finnCap Capital Markets, comments: “We are delighted to have helped raise a further £20m for ANGLE plc, a leading liquid biopsy company, to fund an exciting new clinical programme in prostate cancer and strengthen the balance sheet to support the expansion of its pharma services business ahead of the potential FDA clearance for its Parsortix® PC1 system later this year.”.